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RESPONSE TO TEMOZOLOMIDE IN PATIENTS WITH METASTATIC
MELANOMA IN A THIRD LEVEL CARE HOSPITAL
RESPUESTA A TEMOZOLOMIDA EN PACIENTES CON MELANOMA METASTÁSICO EN UN HOSPITAL
DE TERCER NIVEL DE ATENCIÓN
Selene C. Mejía-Cabrera1,a, G Marín-Márquez 1,b, Fernando Silva-Bravo 2,c, Álvaro J. Montiel-Jarquín2,d,f,
Sandra Maldonado-Castañeda 3,d,f, Arturo García-Galicia 2,e,f

ABSTRACT
Introduction: Melanoma is a public health problem; it represents 4% of malignant skin tumors and is
responsible for 80% of deaths from this type of neoplasm. Objective: Show the response to Temozolomide in
patients with metastatic melanoma. Methods: Descriptive, cross-sectional study. The clinical response of
patients with metastatic melanoma, managed with Temozolomide 200 mg/m2 once a day was analyzed for 5
days every 28 days. The risk factors analyzed were: histological variety, topographic region of the primary lesion,
metastasis, ulceration, and Breslow. Descriptive statistics were used for normality Kolmogorov-Smirnoﬀ,
Student's t-test, and binary logistic regression. Results: There were 51 les, 47 met the criteria; 25 men, 22
women, mean age 54.45, minimum 22, maximum 85 years, Complete response was obtained in 3 (6.3%), partial
response in 7 (14.8%), stable disease in 10 (21%) and disease progression in 27 (57.44%) patients. The presence
of ulceration is associated with a higher Breslow index and, as a result, a higher risk of disease progression.
Conclusions: Temozolomide as monotherapy is a treatment that presents low rates of complete response and
partial response, showing better results in patients with lymph node metastases.
Keywords: Malignant melanoma; Metastasis; Temozolomide. (Source: MeSH NLM).

RESUMEN
Introducción: El melanoma es un problema de salud pública, representa 4% de los tumores malignos de la piel
y es responsable de 80% de las muertes por este tipo de neoplasias. Objetivo: Presentar la respuesta a
Temozolomida en pacientes con melanoma metastásico. Métodos: Estudio descriptivo y transversal. Se analizó
la respuesta clínica de pacientes con melanoma metastásico, manejado con Temozolomida 200 mg/m2 una vez
al día, durante cinco días cada 28 días. Los factores de riesgo analizados fueron: variedad histológica, región
topográ ca de lesión primaria, metástasis, ulceración y Breslow. Se utilizó estadística descriptiva, para
normalidad Kolmogorov-Smirnoﬀ, t de Student, así como regresión logística binaria. Resultados: Fueron 51
expedientes, 47 cumplieron con los criterios; 25 hombres, 22 mujeres, edad media 54,5, mínima 22, máxima 85
años. Se obtuvo una respuesta completa en 3(6%), respuesta parcial 7(14,8%), enfermedad estable en 10(21%) y
progresión de la enfermedad en 27(57,4%) pacientes. La presencia de ulceración se asocia a mayor índice de
Breslow, y como resultado, mayor riesgo de progresión de la enfermedad. Conclusiones: Temozolomida como
monoterapia es un tratamiento que presenta bajas tasas de respuesta completa y respuesta parcial, mostrando
mejores resultados en pacientes con metástasis ganglionares.
Palabras clave: Melanoma maligno; Metástasis; Temozolomida. (Fuente: DeCS BIREME).
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INTRODUCTION
Malignant melanoma (MM) is a malignant neoplasm
that aﬀects the meninges, mucous membranes, and
eyes. Produces a rapidly growing, at, or exophytic,
pigmented lesion; In early stages, it is curable. Lack of
attention leads to lymphatic or hematogenous
metastases with high mortality1,2. It represents 4% of
all malignant skin tumors, responsible for 80% of deaths
from this type of neoplasm. In the United States (US), it
is the fth most common cancer among men and
women. In the world, there are 50,000 deaths per year
due to MM (3,5) .
It occurs at any age; 41% are diagnosed before the age
of 55, from the age of 70, the histological variants of the
nodular and acral lentiginous type are more common
(58%) and in young people, those of super cial

glioblastoma and a decade for the treatment of
metastatic melanoma (4) , at doses of 200 mg/m2 per day,
for ve days, every 28 days (5) however; there is little
literature on the results of managing MM with this drug.
The objective of this study was to report the response to
treatment with Temozolomide in patients with
metastatic MM using the RECIST criteria, in addition to
determining the type of histological variety, the
topography of the melanoma as the primary lesion, the
main metastatic regions of the MM and the relationship
between the presence of ulceration and the Breslow
i n d e x w i t h t h e re s p o n s e t o t re a t m e n t w i t h
Temozolomide.

METHODS
Type of study: a descriptive, cross-sectional study in
patients with stage III or IV metastatic MM.

extension predominate (74%). )(6,7) .
In Mexico, the Melanoma Clinic of the National Cancer
Institute (INCAN) reported an increase of almost 500%
in recent years. It is very common for patients with skin
tumors to seek medical attention in advanced stages,
which means that in most cases, they are no longer
candidates for treatment or have metastatic disease at
the time of diagnosis and after initial treatment (6) .
Systemic treatment oﬀers varying response rates.
Although most patients present with localized disease

Patients: over 18 years of age were included, with
complete medical records, who had initial and control
computerized axial tomography (CAT) or magnetic
resonance imaging (MRI) at the end of treatment, where
target lesions were identi ed for follow-up. Evolution
managed with Temozolomide at 200 mg/m2/day, for
ve days every 28 days (up to 12 cycles in the absence of
disease progression or with unacceptable toxicity);
Patients with a diagnosis of a second primary tumor, a
history of autoimmune disease, or previous treatment
with corticosteroids or biological therapy were
excluded.

at the time of diagnosis and may have cured disease
with surgical removal of the primary tumor in situ; in our
environment, due to the phenotypic characteristics of
the Mexican population, a large part is diagnosed when
they present metastases, a stage in which treatment is
limited, with high mortality (6) .
The Mexican Social Security Institute (IMSS) is one of the
most important public institutions in Latin America,
serving approximately 60%. In 2018, 3,079 cases of
melanoma were recorded in the Mexican population,
constituting 3% of malignant skin neoplasms and 65%
of deaths from cancer (5,7) .
Temozolomide is a drug approved by the Food and
Drug Administration (FDA) for the treatment
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Methods: The data were taken from the clinical le.
Once the patients were identi ed, the contrast imaging
studies were reviewed to determine the target
metastatic lesions, measuring the largest plane
diameter prior to treatment and at the end after 12
months of treatment. The response to treatment was
evaluated according to the radiological criteria of
Response Evaluation in Solid Tumors (RECIST), thus
determining Complete Response (CR), Partial Response
(PR), Stable Disease (SD), or Disease Progression (PD) in
at least one tumor detected by CT or MRI.
Statistics: A non-probabilistic design with convenience
sampling was per formed. The statistics were
descriptive, measures of central tendency and
dispersion mean for ordinal variables, and frequencies
for nominal variables were found.
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The distribution of the variables was determined by the
Levene and Kolmogorov-Smirnov hypothesis tests
reinforced with Lilliefors, which showed a normal
distribution p>0.05.
Binary logistic regression was used to test the
hypothesis, taking the RECIST grade as the dependent
variable and dichotomizing it into 1, complete response
to treatment (CR), and 0 for any other responses. The
independent variables were the type of melanoma,
topographic region, region of metastasis, and Breslow
thickness, which is de ned as the thickness or depth of
the tumor lesion reported in millimeters in the
histopathological study.
Fisher's test for risk (OR), con dence intervals, χ2 Wald
was used. The diﬀerence in means between the Breslow
thicknesses in patients without and with ulceration was
determined with Student's t-test.
The statistical program used was SPSS, v 23 for Windows
and R with its IDE R studio version 4.2.
Ethics: This work complies with the ethical guidelines
for research, and was duly authorized by the local
Health Research Ethics Committee of the “Manuel Ávila
Camacho” Division General Medical Center Specialty
Hospital, Puebla, Mexico, on March 30. August 2021,

with registration number R-2021-2101-090; Anonymity
was maintained at all times, and the data was used
solely for scienti c purposes.

RESULTS
Records of 51 patients diagnosed with MM in treatment
with Temozolomide were collected, in the period from
January 1, 2016, to December 31, 2020. The le of a
patient who was in treatment with monoclonal
antibodies was excluded from the total population. ,
three les were eliminated because they did not have a
histopathological report.
Records of 47 patients were included in the study, of
whom 25 were men and 22 women, with a mean age of
54.5 years (22 to 85 years).
The most frequent histological variety in this
population was rstly nodular melanoma 11(23%),
followed by acral lentiginous melanoma 10(21%) and
epithelioid melanoma 10(21%) respectively, nding
30(66%) of the lesions primaries in pelvic limbs.
Regarding metastatic lesions, it was observed that
pulmonary metastases occurred more frequently,
representing 17 (36%). (Table I)

Table 1. Relación entre los factores de riesgo y RECIST progresiva, así como
características de la población incluida en el estudio.
Factor

Frecuencia

B(X2)

p-value

MET Ganglionar

13

2.09 (4.57)

0.030

7.11

1.21

49

Breslow>4

32

-

0.007

0.059

0.01

0.5

10
11
8
10
2
3
1
1
1

-

0.104
0.060
0.270
0.591
0.828
0.739
0.240
0.384
0.384

-

-

-

10
5
2
30

-

0.591
0.281
0.828
0.886

-

-

-

17
8
9
11

-

0.333
0.886
0.751
0.898

-

-

-

27

-

0.230

-

-

-

Tipo de Melanoma
Melanoma Epiteloide
Melanoma Nodular
Léntigo Maligno
Acral Lentiginoso
Amelánico
Fusiforme
Desmoplásico
Coroideo
Extensión Super cial
Región topográ ca
Cabeza
tórax
Abdomen
Miembro Pélvico
Metástasis
MET Pulmonat
MET Satelite
MET SNC
MET Nodular
Úlcera
Frecuencia

Odds Ratio

IC 95%

Abbreviations: RECIST=Response Evaluation Criteria In Solid Tumors,
β=beta, χ2=chi square, p=likelihood, OR=odds ratio, CI=con dence interval,
MET=metastasis, MM=malignant melanoma, CNS=central nervous system.
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Within the primary objective, in the response rate to
treatment with Temozolomide, this study showed that
according to the RECIST criteria, a Complete Response

was obtained in 3 (6.3%) of the patients, Partial
Response in 7(14.8%), Stable Disease in 10(21%) and
Disease Progression in 27(57.4%) patients. (Figure 1)

Figure 1. Criterios de RECIST para respuesta a tratamiento con Temozolomida en
melanoma metastásico.
No signi cant diﬀerences were observed between the
histological variety and the topographic region of the
primary lesion to present disease progression; however,
it was identi ed that the site of the metastatic lesion
and the presence of Breslow in the primary lesion are
signi cant factors for the evolution and response to
treatment, nding that lymph node metastases are a
factor of better prognosis or protective factor (Odds

ratio=0.123), and Breslow was associated with a risk
factor for disease progression (Odds ratio=0.059), as
shown in Table 1.
Finally, it was established that the presence of
ulceration is associated with a higher index Breslow,
and as a result, increased risk of disease progression
(p=0.00009, Student's t). (Figure 2)

Figure 2. Relación entre el Índice de Breslow y la presencia o ausencia
de ulceración.
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DISCUSSION
MM is a tumor that signi cantly aﬀects society; It aﬀects
people of all ages, with an increase in productive age,
representing a serious and potentially fatal public
health problem in Latin America. In recent decades,
epidemiological data have been collected in Latin
American countries regarding the sociodemographic
characteristics and risk factors for MM in these regions.
We found similarities in the average age of diagnosis. In
the bibliography of Latin American countries, they
reported an average of 60 years. In the anatomical
location, the lower extremity was the most aﬀected in
patients of mestizo race, which coincides with this
population of study (8). We also report diﬀerences; in the
review articles by Fuente-García (8). and Zegarra-del
Carpio9, they reported that the most frequent
histological variety in Mexico and Peru was the acral
lentiginous type (23 and 31%), in this study population
a slight majority of nodular melanoma is found (23 vs
22%), which is characterized by being the most
aggressive histological form, since it presents vertical
growth from the beginning(8,10).
Despite the treatments that have been developed in
the last decade for patients with metastatic melanoma,
due to multiple limitations, cytotoxic chemotherapy
based on Dacarbazine and Temozolomide continues to
be used in our setting.
Temozolomide is an oral alkylating cytostatic agent
derived from Dacarbazine, characterized by the
advantages of being rapidly absorbed orally, crossing
the blood-brain barrier due to its small molecular size
well as relatively low toxicity (11,12).
In patients with advanced melanoma, high CNS
penetration is imperative because most cases of brain
metastases are a major cause of disability and in many
cases, lead directly to death (13,14). The clinical study
carried out in Peru by Lozano-Espinoza (15) reported
mainly regional lymph node metastases at the time of
diagnosis in 50% of the population, and 11.5% with
distant metastases, mainly to the lung, stomach, and
spinal cord. Hoﬀmann et al.16have reported that the
incidence of brain metastases is between 10-40%,
which can be equated in our population, since central
nervous system (CNS) metastases occur in 19.1%,
observing a trend disease progression in patients with
this type of metastatic lesion.

Multiple clinical trials evaluating the eﬃcacy of
Temozolomide as a single agent have been described;
highlights the report by Quirt et al (17) . who conducted a
review of nine phase I or II trials, where observed
response rates ranged from 1% to 29%, with complete
responses observed in 1% to 17% of patients; In this
study conducted in the Mexican population according
to RECIST criteria, 6.3% of patients presented a
complete response and 14.8% a partial response.
Although the histological variety and the topographic
region of the primary lesion did not have signi cant
relevance for the response to treatment, it is observed
that metastases in the lymph node region represent the
majority of the population that had a complete
response to treatment with Temozolomide. Likewise,
the presence of an ulcer in the primary lesion was
associated as the main factor of poor prognosis for
disease progression.
Among the limitations of this study are the selection
bias and the sample size, as well as the limitation in the
study period to determine the survival of patients
treated with Temozolomide; Although systematic
reviews of response to treatment with Temozolomide as
monotherapy have been carried out, the diﬀerences in
the number of the population, its characteristics, and
the established doses of Temozolomide, are not
completely comparable to this study.
Likewise, in Mexico, there have been no studies of
response to treatment based on this cytotoxic.
Therefore, the results of this research study are relevant
since it focuses on evaluating the response to treatment
to propose the best use of the drug—temozolomide in
MM, which presented a complete response in patients
with lymph node and satellite metastases. In many Latin
American countries, geographic or nancial limitations
may prevent patients from accessing basic medical
care, or access to current rst-choice treatments for
advanced-stage melanoma, such as PD-1 inhibitors,
mainly pembrolizumab and nivolumab, as well as CTLA4 inhibitors such as ipilimimab (18) .
The results of this study open the discussion on the
cost/bene t of therapies such as immunotherapy,
which have shown an increase in disease-free life,
mainly in the public health sector, to oﬀer better
survival and quality of life in this oncopathogenesis, as
well as to make Emphasis on primary prevention
measures and campaigns.
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CONCLUSION

response to treatment with Temozolomide.

The objective of this study was to report the response to
treatment with Temozolomide in patients with
metastatic MM using the RECIST criteria, in addition to
determining the number of patients by age and sex, the
type of histological variety, the topography of
melanoma as a primary lesion, the main metastatic
regions of the MM and the relationship between the
presence of ulceration and the Breslow index with the

Temozolomide as monotherapy is a reasonable
therapeutic option if surgery is not appropriate; it
presents low partial and complete response rates with
better results in lymph node metastases. The most
frequent histological variety is nodular melanoma. At
the time of diagnosis, the presence of ulceration in the
primary lesion represents a poor prognosis and risk
factor for response to treatment.
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